Phil Adamson is Vice President, Global Clinical Affairs and Medical Director at St. Jude Medical. In this capacity, Dr. Adamson is responsible for global development of St. Jude’s heart failure formulary spanning cardiac resynchronization therapy to the CardioMEMS HF™ system. Dr. Adamson joined St. Jude Medical in February 2015.
Dr. Adamson received his M.D. (with distinction) and Masters of Science in Cardiovascular Physiology from the University of Oklahoma Health Sciences Center. He holds a Bachelor of Science with dual majors in Accounting and Physiology from the University of Central Oklahoma. Dr. Adamson trained in internal medicine and cardiology at the University of Oklahoma Health Sciences Center and received a National Research Service Award from the National Institutes of Health in support of his Cardiology Fellowship. He joined the faculty at the University of Oklahoma as a Warren Foundation Investigator and received R01 funding from the National Institutes of Health to develop a novel model of ischemic heart failure that served to investigate the autonomic mechanisms of sudden cardiac death. Dr. Adamson’s clinical interests focused on development of more efficient and effective disease management systems for patients with chronic heart failure specifically focusing on remote monitoring of physiologic signals from implanted devices. His work developing heart rate variability monitoring was an important stimulus to develop a link between electrophysiology and heart failure management using implantable technology. Dr. Adamson remains an Adjunct Associate Professor of Physiology at the University of Oklahoma Health Sciences Center and is a distinguished alumnus of the University of Central Oklahoma.
Dr. Adamson helped developed a novel cardiology training curriculum designed to provide skills in device implantation and management along with expertise in out-patient multidisciplinary disease management program development. He has served as the Principal Investigator or on the Steering Committees of several large randomized clinical trials. In this capacity he was the Co-PI of the CHAMPION Trial which demonstrated the efficacy and safety of the CardioMEMS HF™ System, leading to FDA approval of the system in May 2014.